[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624374":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":46,"responsibleParty":66,"collaborators":26,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":26,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":26,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Bangladesh Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Transarterial chemoembolization and lenvatinib","EXPERIMENTAL","Participants in this arm will receive transarterial chemoembolization (TACE) followed by oral lenvatinib therapy at standard weight-based dosing. TACE will be performed according to institutional protocol, and lenvatinib will be initiated after the patient has recovered from the TACE procedure. Multiple sessions of TACE will be considered.",[13,14],"Procedure: TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib)","Drug: Lenvatinib",{"label":16,"type":17,"description":18,"interventionNames":19},"Lenvatinib","ACTIVE_COMPARATOR","Participants in this arm will receive oral lenvatinib monotherapy at standard weight-based dosing.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib)","Transarterial Chemoembolization will be done in the radiology department by an interventional radiologist. Lenvatinib will be started after 7 days following TACE according to body weight (8mg\u002Fday in patients with a body weight \\\u003C60 kg and 12mg\u002Fday in patients with a body weight of 60 kg or more)",[9],null,{"type":28,"name":16,"description":29,"armGroupLabels":30,"otherNames":26},"DRUG","Lenvatinib will be started according to body weight ((8mg\u002Fday in patients with a body weight \\\u003C60 kg and 12mg\u002Fday in patients with a body weight of 60 kg or more)",[16,9],[32,35],{"name":33,"affiliation":26,"role":34},"Md. Ayub Al Mamun, FCPS (Medicine)","STUDY_CHAIR",{"name":36,"affiliation":26,"role":37},"Sourav Kumar Chakraborty","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":26,"email":42},"CONTACT","+8801747473455","drsouravhepato@gmail.com",{"name":33,"role":40,"phone":44,"phoneExt":26,"email":45},"+8801725876589","ayubmamunal@gmail.com",[47],{"facility":48,"status":49,"city":50,"state":26,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Department of Hepatology, Bangladesh Medical University","RECRUITING","Dhaka","1000","Bangladesh","BD",{"type":55,"coordinates":56},"Point",[57,58],90.40744,23.7104,{"lat":58,"lon":57},[61,63],{"name":62,"role":40,"phone":44,"phoneExt":26,"email":45},"Md. Ayub Al Mamun Professor, Department of Hepatology, BMU, FCPS ( Medicine )",{"name":64,"role":40,"phone":65,"phoneExt":26,"email":26},"Asma Helen Khan Assistant Professor, Department of Hepatology, BMU, FCPS ( Hepatology)","+8801732242310",{"type":37,"investigatorFullName":36,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Resident, Phase B- MD ( Hepatology), Department of Hepatology, Bangladesh Medical University","100624374","comparison-of-response-between-combination-of-transarterial-chemoembolization-and-lenvatinib-therapy-versus-lenvatinib-monotherapy-in-patients-with-unresectable-hepatocellular-carcinoma-100624374",false,"NCT07408804","Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 years,\n2. Hepatocellular carcinoma, confirmed by dynamic CT scan \u002F MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,\n3. At least one measurable lesion based on mRECIST criteria,\n4. ECOG performance status 0-2,\n\nExclusion Criteria:\n\n1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,\n2. Hepatocellular carcinoma with main trunk portal vein thrombosis,\n3. Child Turcotte Pugh Score 10 ( C) or more,\n4. ALBI grade 3,\n5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,\n6. Known allergy or intolerance to lenvatinib .","ALL","18 Years","75 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82],"NA","The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.",[85],"Unresectable Hepatocellular Carcinoma (HCC)","2026-02-06",{"date":88,"type":89},"2026-02-13","ACTUAL",{"date":91,"type":89},"2025-04-08",{"date":93,"type":79},"2026-09-30",{"name":5,"class":6},1]